MedPacto, Announces the formation of the Clinical Advisory Board for speeding up its new drug development and out-licensing
Oct 24, 2022
Former President at Moderna Therapeutics including 4 other world-class clinical experts have been appointed…
Medpacto (CEO Seong-jin Kim), a genome-based drug discovery and a clinical-stage biotechnology company, announced that Greg Licholai, the former President of rare disease at Moderna Therapeutics, has been appointed to the Company’s Clinical Advisory Board with 4 other world-class bio experts on the 24th.
The Clinical Advisory Board will bring comprehensive expertise on new drug development, out-licensing, and commercialization strategy for its new drug candidate targeting bone diseases that will be open to the public shortly.
The Clinical Advisory Board includes clinical specialists who will develop MedPacto’s first-in-class new drug candidate for the treatment of bone diseases such as osteosarcoma and rheumatoid arthritis.
Other than Greg Licholai, the members of the Clinical Advisory Board are as follows: John Letterio, Associate Director of the Seidman Cancer Center at Cleveland Medical Center, Hyun Bae, Orthopedist at Cedars-Sinai Medical Center, Isaac Kim, Department Chief of Urology, Yale University School of Medicine and Greg Licholai, former Head of Rare Diseases at Moderna.
Dr. Greg Licholai, MD is the Chief Medical & Innovation Officer at ICON plc., a leading clinical research organization, had previously served as the President of rare diseases at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals and partner at McKinsey & Co. where he ran the healthcare data service line. Based on his deep knowledge and hands-on experience, Dr. Licholai will be providing his expertise on commercialization strategies including global clinical strategy and out-licensing for MedPacto’s new drug candidate.
Dr. Hyun Bae, MD is a distinguished spine fellowship and trained board-certified orthopedic surgeon practicing at Spine-center at Cedars-Sinai Medical Center and the Spine Institute in Santa Monica CA. His specialties lie in the repair of In Vitro Diagnostics (IVD) and evaluating instrumentation for spinal fusion and grafting materials. Dr. Bae has written or co-authored more than 70 published scientific papers and has around 30 patents.
Dr. John Letterio, MD is an interim director of UH Seidman Cancer Center at Cleaveland Medical Center and a Division Chief at the Cancer Research Center at UH Rainbow Babies and Children’s Hospital, Case Western Reserve University (UH BR&C). Dr. John Letterio and Dr. Seong-jin KIM, CEO of MedPacto, have been working together for a long time since their time at the National Institutes of Health (NIH).
As a distinguished oncologist, Dr. John Letterio is well-versed in the field of bone metastases. He will be providing his clinical knowledge to further develop a clinical strategy for MedPacto’s new drug candidate for the treatment of bone diseases.
As a urology oncologist, Dr. Isaac Kim is currently serving as a professor of urology and the head of the department at Yale University School of Medicine. With his extensive clinical experience in urological oncology including androgen signaling of prostate cancer in the tumor microenvironment, Dr. Kim is currently practicing a clinical trial for bone metastasis of urinary cancer.